Row64 - The Industry's Breakthrough Visual Real-Time Business Intelligence Platform Secures Strategic Funding
CHEYENNE, WY / ACCESS Newswire Row64, creators of the only visual real-time business intelligence platform for big data, today announced its $4 million seed funding round led by Galaxy Interactive, with participation from Alumni Ventures and Differential Ventures. Based on the momentum from market traction across various industries, the capital will further fuel the expansion of Row64's development roadmap and go-to-market teams, accelerating product innovation and global market adoption.
In today's fast-paced, data-driven economy, enterprises face an overwhelming surge in the volume, velocity, and variety of data. Yet most legacy business intelligence systems are not equipped to deliver the real-time, visual insights needed to act on that information as it happens. As a result, organizations often miss critical opportunities or react too late to rapidly changing conditions. With global data creation expected to surpass 400 terabytes per day (the equivalent of 20 trillion high-res photos), solving this challenge has become essential to maintaining a competitive edge.
Row64 is the only visual real-time business intelligence platform delivering interactive analysis for massive data sets. Built on a GPU- and CPU-accelerated computing stack, Row64's high-throughput, low-latency processing updates data at sub-millisecond speeds while powering a new generation of highly interactive dashboards. As a result, businesses can react faster to changing conditions and take advantage of opportunities as they arise.
'Real-time is the new standard for modern business intelligence,' said Marc Stevens, CEO and co-founder of Row64. 'With our platform, enterprise customers can visualize and interact with massive, and even streaming, datasets instantly, empowering them to make the critical, fast-paced decisions that drive competitive advantage.'
Row64 next-generation dashboards are built from the ground up to push the boundaries of scalability and real-time performance. Utilizing Row64's native browser front end powered by Web Assembly (WASM) and WebGL, users across the organization interact with GPU-rendered dashboards with detail and accuracy, capable of compositing rich data such as 2D and 3D GIS data, images, and line networks, all at ultra-high resolution (4k and 8k monitors) and interactive (60fps+) frame rates on billion-record datasets.
Key benefits of Row64 include:
'Galaxy Interactive invests in transformative technologies and outstanding teams, and is proud to back Row64 as it builds a new full stack and defines a new category in business intelligence,' said Jeff Brown, Partner at Galaxy Interactive. 'Their visual, real-time business intelligence platform solves a critical market gap, transforming how data-driven organizations operate in high-velocity environments.'
Row64's speed, scale, flexibility, and visual precision support a wide range of use cases, including multivariate P&L analysis, spatial analytics for intelligent cities, real-time cybersecurity, motion analysis, HR organizational analysis, and complex systems analysis for emergency incident reporting.
Highlighting another industry first, Row64 will demonstrate its breakthrough new DeltaStream -powered Apache Kafka data pipeline for low latency, real-time data streaming, and interactive analysis, at the Databricks Summit in San Francisco, June 9-10. 2025 (Booth #F615).
For more information or to schedule a demo, visit www.row64.com.
ABOUT ROW64:
Row64 provides the world's first visual real-time business intelligence platform, empowering the enterprise to gain immediate insights from massive datasets. Built on an accelerated computing stack, Row64 allows its customers to visualize and interact with big data instantly, enabling immediate, informed decision-making across the enterprise. Learn more at https://row64.com/.
ABOUT GALAXY INTERACTIVE:
Galaxy Interactive invests in transformative technology, content, and the infrastructure powering the convergence of our digital and physical lives. We back companies at the forefront of interactive content, spatial computing, edge AI, and real-time data protocols and invest across the full compute stack – from edge silicon to cloud. It was founded in 2018 and is based in New York, New York. Learn more at https://interactive.galaxy.com/.
MEDIA CONTACT:
Nina Pfister, MAG PR
nina@mooringadvisorygroup.com
SOURCE: Row64
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
9 hours ago
- Associated Press
Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison
Imagene AI delivers a living intelligence engine for adaptive, insight-driven precision medicine. MIAMI, FL / ACCESS Newswire / July 1, 2025 / Imagene AI, a pioneer in multi‑modal foundation models for precision medicine, today announced the successful close of a $23 million Series B financing round led by Oracle Chairman and CTO Larry Ellison. This latest infusion brings Imagene AI's total capital raised to $45 million under terms that reflect the company's accelerating momentum and expanding strategic footprint. The round also included participation from existing investor Aguras Pathology Investments. 'We are honored to have the continued support of one of the world's foremost technology visionaries,' said Dean Bitan, CEO and Co‑founder of Imagene AI. 'We're developing the core intelligence that allows precision medicine to function as an adaptive, insight-driven system - from real-time trial design to rapid patient identification and more informed clinical decisions. Our goal is to make every trial more responsive, every insight more actionable, and every patient journey more personalized.' 'Imagene AI's ability to unite imaging, omics, and clinical data in a single foundation model is exactly the kind of breakthrough we believe will drive the next generation of drugs and diagnostics,' said Larry Ellison, Oracle Chairman and CTO. 'Their approach opens the door to a more adaptive, biologically fluent era of precision medicine.' Powering Living Precision Medicine Through Adaptive Intelligence At the core of Imagene AI is a dynamic intelligence infrastructure, an orchestration layer that continuously evolves with every stream of biological and clinical data. Histopathology, molecular profiles, and clinical context are routed in real-time through our proprietary foundation models, large language models, and biology-tuned analysis continuous loop ensures insights remain current and biologically grounded, empowering clinicians and researchers with personalized, up-to-date guidance at every stage of the trial. This momentum builds on a series of important milestones. Imagene AI's state-of-the-art digital pathology foundation model, trained on more than 1.5 million biopsy images, has demonstrated benchmark performance in key research tasks, particularly when working with limited data, a challenge common in real-world scenarios. The company launched the OI Suite platform to a broader community of users, including non-AI experts, delivering capabilities for biomarker discovery, indication expansion, and patient identification across multiple therapeutic areas. Additionally, Imagene AI is expanding strategic collaborations, such as its partnership with Tempus, to bring rapid predictive assays to more clinicians and patients, guiding treatment decisions with greater precision. Contact InformationAvital Rabani VP of Marketing SOURCE: Imagene press release
Associated Press
11 hours ago
- Associated Press
'Why International Students Are Getting Scammed Out of Safe Housing And How StudentsLanding Is Fighting Back'
BOSTON, MA / ACCESS Newswire / July 1, 2025 / For international students, securing housing in the U.S. often feels like navigating a minefield blindfolded. Stories of wire transfer scams, fake listings and substandard living conditions have become all too common in student communities across America. Yet for thousands of international students arriving in Boston each year, one platform has emerged as a beacon of trust in an otherwise chaotic landscape: StudentsLanding. The company now commands over 50% of the international student housing market in Boston and they're rapidly expanding to tackle the same problems in New Jersey and San Francisco. When Dreams Meet Reality Checks The path to U.S. education is paved with bureaucratic hurdles, but for many international students, housing represents the most treacherous obstacle of all. Picture this: You're a 22-year-old from Mumbai who's just secured admission to MIT. You've conquered entrance exams, visa interviews and financial documentation. But now you're faced with finding safe, affordable housing in a city you've never visited, using websites you don't trust, dealing with landlords who may not even exist. The stakes couldn't be higher. A bad housing decision doesn't just mean discomfort - it can derail an entire academic journey. The Scam Epidemic: Real Stories from the Ground The horror stories are disturbingly common. Take Priya, a graduate student from Delhi who found what seemed like the perfect apartment near Harvard on Craigslist. The 'landlord' requested a $2,000 security deposit via wire transfer before she could view the property. After sending the money, she discovered the listing was fake - the real property owner had never heard of her supposed landlord. On Facebook Marketplace, another student from Shanghai fell victim to a sophisticated rental scam. The fraudster had copied legitimate photos from a real estate website and created a convincing fake listing for a Back Bay apartment. Even established platforms aren't immune. On popular rental sites, students regularly encounter 'too good to be true' listings - luxury apartments at suspiciously low prices that turn out to be bait-and-switch schemes. Students wire money for apartments that either don't exist or are significantly different from what was advertised. 'Many students were losing money or ending up in poor housing situations because they didn't understand the U.S. system,' explains Siddhey Mahadik, Chief Operating Officer of StudentsLanding. 'We created a platform that makes their entire housing journey smooth, safe, and transparent.' The Trust Infrastructure Problem Traditional rental platforms weren't built for international students. They assume local knowledge, established credit histories and the ability to physically inspect properties. For someone coordinating their move from halfway around the world, these assumptions create dangerous blind spots. StudentsLanding recognized that international students needed more than just listings - they needed an entire support ecosystem. One that could bridge the gap between overseas preparation and on-ground reality. The company's approach centers on three core pillars: Verified Everything: Every listing, landlord and lease agreement goes through rigorous verification processes. No more wondering if that too-good-to-be-true apartment is actually a scam. Global Partnership Network: StudentsLanding works directly with overseas education counselors particularly in countries like India who serve as trusted advisors during the planning phase. These partnerships ensure students receive guidance from people who understand both their home country context and U.S. realities. Operations Excellence: Perhaps most importantly, StudentsLanding has built what Mahadik calls a 'high-performing operations team' that works across time zones to provide real-time support throughout the entire housing process. Beyond Transactions: Building Student Success What sets StudentsLanding apart isn't just what they do, it's how they do it. While competitors focus on transactions, StudentsLanding focuses on transformation. 'Our operations team is what truly sets us apart,' Mahadik says. 'They're not just service providers - they're problem-solvers working across time zones to make sure every student lands safely.' This human-centered approach has resonated particularly well with students attending Boston's prestigious institutions. StudentsLanding currently serves students from: The company's success in Boston hasn't gone unnoticed. According to Akhilesh Benke, Director of India Operations, the overseas counselor partnerships have been instrumental in scaling their impact. 'Our partnerships with overseas counselors have been the best part of our growth,' Benke explains. 'They help us serve a diverse set of clients on a single, unified platform tailored to their needs.' Scaling Trust Across America With a dominant position in Boston secured, StudentsLanding is now applying the same formula to New Jersey and San Francisco - two markets where international student populations are growing rapidly but housing solutions remain fragmented. 'These are natural next steps,' Mahadik notes. 'We're applying the same formula - trusted partners, verified housing and human support to cities where students face the same issues we saw in Boston.' The expansion strategy reflects a broader understanding of how trust scales in global markets. Rather than simply copying their Boston playbook, StudentsLanding is building local partnerships and verification networks that can deliver the same quality of service in different regulatory and cultural contexts. The Infrastructure of Opportunity StudentsLanding represents something larger than a housing platform - it's part of the infrastructure that enables global talent mobility. For students, the value proposition is clear: instead of spending months worrying about housing scams and substandard conditions, they can focus on what brought them to America in the first place, their education and career aspirations. For universities, StudentsLanding provides an additional layer of support that helps ensure their international students have successful experiences both inside and outside the classroom. 'In an industry filled with cold real estate platforms and transactional tools, we're offering something rare - reliability, education and peace of mind,' the company states. 'For international students starting a new chapter, that makes all the difference.' As StudentsLanding expands nationwide, they're not just growing a business - they're building the infrastructure that enables the next generation of global leaders to thrive in America. In a world where talent knows no borders, that infrastructure has never been more important. Contact Info: Name of person: Abhishek Benke Email: [email protected] Address: 119 Braintree St Ste 207 Boston MA 02134 Phone: 857-381-3062 Website: SOURCE: Studentslanding press release
Indianapolis Star
18 hours ago
- Indianapolis Star
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CALIFORNIA / ACCESS Newswire Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration. 'We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,' said Dinesh V. Patel, PhD, President and CEO of Protagonist. 'PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.' PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026. 'While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,' added Dr. Patel. 'We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.' Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30 th at 4:30 pm ET are: US-based Investors: 1-877-407-0752 International Investors: 1-201-389-0912 Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors cdavis@ +1 212 915 2577 Media Relations Contact Virginia Amann ENTENTE Network of Companies virginiaamann@ +1 833 500 0061 ext. 1 SOURCE: Protagonist Therapeutics View the original press release on ACCESS Newswire
